Myelodysplastic syndrome Trials in Nashville, United States
Conditions / Myelodysplastic syndrome / Nashville, United States
Research into Myelodysplastic syndrome spans multiple therapeutic approaches and trial phases.
24 total trials for this combination
Showing top 10 of 24 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00412360 | Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501) | COMPLETED | PHASE3 |
| NCT01522976 | Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia | ACTIVE_NOT_RECRUITING | — |
| NCT07422480 | A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions | RECRUITING | PHASE3 |
| NCT00965861 | SCRI Tissue Testing Registry | TERMINATED | — |
| NCT05457556 | Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT04726241 | The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study | RECRUITING | PHASE1/PHASE2 |
| NCT02521493 | Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT02719574 | Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation | COMPLETED | PHASE1/PHASE2 |
| NCT05316701 | Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03268954 | Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) | COMPLETED | PHASE3 |